The global retinal vein occlusion treatment market is expected to be valued at US$ 2.3 billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 5.9% to reach US$ 4.7 billion during forecast 2023 to 2033. Retinal vein occlusion is one of the most prevalent retinal vascular illnesses in older individuals, primarily affecting people over the age of 65. Age is a major potential risk for retinal vein occlusion. As the geriatric population rises, it is expected that the incidence of retinal vein occlusion will emerge as well.
Players in the retinal vein occlusion treatment market are expanding their capacity for producing corticosteroid drugs, which can aid in combating the inflammatory elements that cause edema. Medical practitioners, on the other side, are increasingly becoming proficient in focal laser therapy. This treatment applies lasers to places of swelling, allowing edema to reduce. Many retinal vein occlusion market stakeholders are investing more in pan-retinal photocoagulation therapy advancement and research. In instances of BRVO with neovascularization or macular edema, anti-vascular endothelial growth factor (anti-VEGF) medicines including Lucentis, Avastin, and Eylea are often used.
Moreover, increased medication authorization for the diagnosis of RVO patients contributes to industry growth. For instance, the Food and Drug Administration (FDA) certified the first biosimilar drug, Byooviz (ranibizumab-nuna) evolved by Samsung Bioepis, for the treatment of individuals with macular degeneration and other eye diseases such as RVO in September 2021. This authorization should augment overall growth.
Moreover, increased medication authorization for the diagnosis of RVO patients contributes to industry expansion. For instance, the Food and Drug Administration (FDA) certified the first biosimilar drug, Byooviz (ranibizumab-nuna) evolved by Samsung Bioepis, for the treatment of individuals with macular degeneration and other eye diseases such as RVO in September 2021. This authorization should augment overall growth.
Due to various effective healthcare facilities, an increment in the pervasiveness of eye disorders, sophisticated technology, and a boost in the ageing population, North America held a significant portion of the global retinal vein occlusion market in 2022. From 2023 to 2033, the Asia Pacific retinal vein occlusion market is predicted to grow at a 6.5% CAGR. The increasing prevalence of eye conditions in Asia Pacific, particularly in China, Singapore, Indonesia, and other Southeast Asian countries, as well as rising healthcare spending, are predicted to propel market expansion in Asia Pacific from 2023 to 2033.
The retinal vein occlusion industry in the Middle East and Africa is expected to grow due to the presence of a sophisticated medical system. Due to limited access to medical infrastructure and the sluggish advancement of the healthcare industry, the MEA market is expected to grow gradually. Nations such as Kuwait and Qatar, on the other hand, are focusing more on the medical industry and burgeoning healthcare facilities, which will strengthen the region's industry. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.
Data Points | Key Statistics |
---|---|
Expected Market Value (2023) | US$ 2.3 billion |
Anticipated Forecast Value (2033) | US$ 4.7 billion |
Projected Growth Rate (2023 to 2033) | 5.9% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The decline in industry growth was mainly due to the COVID-19 pandemic, which has resulted in strict containment approaches such as social distancing, remote employment, and the closure of industries and other economic operations, deriving in organizational hardships. The entire distribution chain has been impacted, which has had a negative impact on the retinal vein occlusion treatment market in the past.
However, now, that the industries are getting back to their normal functioning, the global demand for retinal vein occlusion treatment is projected to increase at a CAGR of 5.9% during the forecast period between 2023 and 2033, reaching a total of US$ 4.7 billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5%.
The rising prevalence of Atherosclerosis and diabetes drives market expansion
The increased incidence of atherosclerosis and diabetes is predicted to drive market expansion. Because atherosclerosis is primarily asymptomatic, determining the prevalence rate is hard. Atherosclerosis is widely regarded as the leading cause of cardiovascular disease. As a result, the increasing incidence of cardiovascular diseases is attributed to the retinal vein occlusion treatment industry growth.
Based on the International Diabetes Federation (IDF), approximately 537 million adults suffered from diabetes in 2021, with this figure expected to rise to 643 million by 2030 and 783 million by 2045. In addition, approximately 610,000 deaths occur from heart disease in the United States annually. That equates to one out of every four deaths.
Coronary heart disease is the main cause of mortality in the Western world, claiming the lives of over 370,000 people each year as per the report published in the National Library of Medicine. As a result, expanding the pervasiveness of secondary conditions may boost RVO incidence and industry growth.
Availability of Multiple Medical Therapies to fuel Market Growth
Presently, there is no therapeutic option to reverse retinal vein occlusions. There are, nevertheless, numerous medical therapies obtainable to control RVO complications. Anti-VEGF injections, corticosteroid drugs, focal laser therapy, and pan-retinal photocoagulation therapy are a few of the therapy methods. Anti-VEGF injection therapy is regarded as the first curative therapy for patient populations with BRVO or CRVO who have macular edema.
Anti-VEGF therapy has resulted in significant advances in macular edema patients. For those who suffer from macular edema, corticosteroids, such as dexamethasone implant (OZURDEX) are termed second-line therapy. Therefore, the prevalence of various therapies is predicted to drive market growth.
High Costs to Hinder Market Growth
The demand is anticipated to be hindered by the present unmet medical needs in the retinal vein occlusion industry for care that restores vision while remaining inexpensive.
There is no doubt that the emergence of biosimilars into the Retinal vein occlusion market will reduce expansion in the forthcoming years. During the projected timeframe, high treatment-related expenses and linked side effects of these treatments are anticipated to stymie demand.
Extensive Development of Ophthalmology Infrastructure of the Pharmaceutical Industry to drive growth
North America would retain a huge proportion throughout the forecast timeframe. The USFDA's authorization of advanced anti-VEGF medicines in the US, the pharma industry's massive ophthalmology infrastructure, and recurring medical studies for retinal ailments all contribute to the industry's growth.
Moreover, according to the report published in Vitreous Retina Macula Consultants of New York, New York ophthalmologists and retinal ocular specialists release more research on the therapeutic interventions for branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) in the leading peer-reviewed publications than any other personal or scholarly group in the USA. Also, they created numerous existing theories in retinal disease and several of the best therapeutic approaches recognized worldwide. As a result, this factor is expected to propel the market.
Regulatory Drug Approvals drive Regional Market Growth
Europe is expected to have the second-largest sales volume during the forecast years owing to the high prevalence of regulatory drug approvals. The Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom approved marketing approval for Ximluci, a ranibizumab biosimilar created in collaboration between STADA Arzneimittel and Xbrane Biopharma, in January 2023. Since the approval of Teva Pharmaceuticals' Ongavia in May 2022, this is the 2nd ranibizumab biosimilar for the UK industry. Ranibizumab is a vascular endothelial growth variable obstacle used to cure retinal diseases such as retinal vein occlusion.
According to a 2018 Pubmed report, the random-effects gathered incidence of RVO in Europeans over the age of 55 was 0.7%. The overall population of affected people in the EU is expected to increase by nearly 20%, from 900,000 in 2018 to 1.1 million in 2050. The rise of a huge aged population, along with high healthcare investment, are the other attributes driving the retinal vein occlusion market expansion in this region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Branch Retinal Vein Occlusion segment held the highest market share globally
In 2022, the branch retinal vein occlusion segment held the largest global retinal vein occlusion therapeutics revenue growth. As a result of the growing incidence of elevated blood pressure, cardiovascular disease, and glaucoma, this segment is predicted to dominate the market. This segment is anticipated to expand at a CAGR of 6% over the forecast timeframe.
Hospitals are Estimated to Hold the Largest Share
In 2022, the hospital segment led the market, accounting for 46% of total revenue. Hospitals are usually regarded as primary healthcare systems, and the patient population's priority for hospitals for the assessment and treatment of chronic disorders is also stirring up segment growth.
Key players in the Retinal Vein Occlusion Treatment market are AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Kodiak Sciences Inc, Chugai Pharmaceuticals, Novartis AG. Some of the latest developments by the manufacturers are below
Report Attribute | Details |
---|---|
Market Value in 2023 | US$ 2.3 billion |
Market Value in 2033 | US$ 4.7 billion |
Growth Rate | CAGR of 5.9% from 2023 to 2033 |
Base Year for Estimation | 2022 |
Historical Data | 2018 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
The market value for 2023 is US$ 2.3 billion.
Through 2033, market sales are likely to rise at a 5.9% CAGR.
The market rose at a 5% CAGR from 2018 to 2022.
Growing preference for biosimilars could hinder market growth.
Branch retinal vein occlusion is likely to be the key type segment through 2033.
1. Executive Summary | Retinal Vein Occlusion Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Ranibizumab 5.3.2. Dexamethasone 5.3.3. Aflibercept 5.3.4. Bevacizumab 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033 6.3.1. Central Retinal Vein Occlusion 6.3.2. Branch Retinal Vein Occlusion 6.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis , 2023 to 2033 7.3.1. Optical Coherence Tomography 7.3.2. Fundoscopic Examination 7.3.3. Fluorescein Angiography 7.4. Y-o-Y Growth Trend Analysis By Diagnosis , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Diagnosis , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 8.3.1. Hospitals 8.3.2. Research and Academics 8.3.3. Specialty Clinics 8.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. South Asia 9.3.5. East Asia 9.3.6. Oceania 9.3.7. Middle East & Africa 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. The United States 10.2.1.2. Canada 10.2.2. By Drug Class 10.2.3. By Type 10.2.4. By Diagnosis 10.2.5. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Type 10.3.4. By Diagnosis 10.3.5. By End User 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Drug Class 11.2.3. By Type 11.2.4. By Diagnosis 11.2.5. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Type 11.3.4. By Diagnosis 11.3.5. By End User 11.4. Key Takeaways 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. United Kingdom 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Drug Class 12.2.3. By Type 12.2.4. By Diagnosis 12.2.5. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Type 12.3.4. By Diagnosis 12.3.5. By End User 12.4. Key Takeaways 13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Malaysia 13.2.1.3. Singapore 13.2.1.4. Thailand 13.2.1.5. Rest of South Asia 13.2.2. By Drug Class 13.2.3. By Type 13.2.4. By Diagnosis 13.2.5. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Type 13.3.4. By Diagnosis 13.3.5. By End User 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug Class 14.2.3. By Type 14.2.4. By Diagnosis 14.2.5. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Type 14.3.4. By Diagnosis 14.3.5. By End User 14.4. Key Takeaways 15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. Australia 15.2.1.2. New Zealand 15.2.2. By Drug Class 15.2.3. By Type 15.2.4. By Diagnosis 15.2.5. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Type 15.3.4. By Diagnosis 15.3.5. By End User 15.4. Key Takeaways 16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. South Africa 16.2.1.3. Israel 16.2.1.4. Rest of MEA 16.2.2. By Drug Class 16.2.3. By Type 16.2.4. By Diagnosis 16.2.5. By End User 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Drug Class 16.3.3. By Type 16.3.4. By Diagnosis 16.3.5. By End User 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2022 17.1.2.1. By Drug Class 17.1.2.2. By Type 17.1.2.3. By Diagnosis 17.1.2.4. By End User 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2022 17.2.2.1. By Drug Class 17.2.2.2. By Type 17.2.2.3. By Diagnosis 17.2.2.4. By End User 17.3. Brazil 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2022 17.3.2.1. By Drug Class 17.3.2.2. By Type 17.3.2.3. By Diagnosis 17.3.2.4. By End User 17.4. Mexico 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2022 17.4.2.1. By Drug Class 17.4.2.2. By Type 17.4.2.3. By Diagnosis 17.4.2.4. By End User 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2022 17.5.2.1. By Drug Class 17.5.2.2. By Type 17.5.2.3. By Diagnosis 17.5.2.4. By End User 17.6. UK 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2022 17.6.2.1. By Drug Class 17.6.2.2. By Type 17.6.2.3. By Diagnosis 17.6.2.4. By End User 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2022 17.7.2.1. By Drug Class 17.7.2.2. By Type 17.7.2.3. By Diagnosis 17.7.2.4. By End User 17.8. Spain 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2022 17.8.2.1. By Drug Class 17.8.2.2. By Type 17.8.2.3. By Diagnosis 17.8.2.4. By End User 17.9. Italy 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2022 17.9.2.1. By Drug Class 17.9.2.2. By Type 17.9.2.3. By Diagnosis 17.9.2.4. By End User 17.10. India 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2022 17.10.2.1. By Drug Class 17.10.2.2. By Type 17.10.2.3. By Diagnosis 17.10.2.4. By End User 17.11. Malaysia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2022 17.11.2.1. By Drug Class 17.11.2.2. By Type 17.11.2.3. By Diagnosis 17.11.2.4. By End User 17.12. Singapore 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2022 17.12.2.1. By Drug Class 17.12.2.2. By Type 17.12.2.3. By Diagnosis 17.12.2.4. By End User 17.13. Thailand 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2022 17.13.2.1. By Drug Class 17.13.2.2. By Type 17.13.2.3. By Diagnosis 17.13.2.4. By End User 17.14. China 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2022 17.14.2.1. By Drug Class 17.14.2.2. By Type 17.14.2.3. By Diagnosis 17.14.2.4. By End User 17.15. Japan 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2022 17.15.2.1. By Drug Class 17.15.2.2. By Type 17.15.2.3. By Diagnosis 17.15.2.4. By End User 17.16. South Korea 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2022 17.16.2.1. By Drug Class 17.16.2.2. By Type 17.16.2.3. By Diagnosis 17.16.2.4. By End User 17.17. Australia 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2022 17.17.2.1. By Drug Class 17.17.2.2. By Type 17.17.2.3. By Diagnosis 17.17.2.4. By End User 17.18. New Zealand 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2022 17.18.2.1. By Drug Class 17.18.2.2. By Type 17.18.2.3. By Diagnosis 17.18.2.4. By End User 17.19. GCC Countries 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2022 17.19.2.1. By Drug Class 17.19.2.2. By Type 17.19.2.3. By Diagnosis 17.19.2.4. By End User 17.20. South Africa 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2022 17.20.2.1. By Drug Class 17.20.2.2. By Type 17.20.2.3. By Diagnosis 17.20.2.4. By End User 17.21. Israel 17.21.1. Pricing Analysis 17.21.2. Market Share Analysis, 2022 17.21.2.1. By Drug Class 17.21.2.2. By Type 17.21.2.3. By Diagnosis 17.21.2.4. By End User 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Drug Class 18.3.3. By Type 18.3.4. By Diagnosis 18.3.5. By End User 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. AbbVie 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.2. F. Hoffmann- La Roche AG 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.3. Regeneron Pharmaceuticals 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.4. Taiwan Liposome Company 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.5. Aerie Pharmaceuticals 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.6. Graybug Vision 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.7. Outlook Therapeutics 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.8. Kodiak Sciences Inc. 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.9. Chugai Pharmaceuticals Co. Ltd. 19.1.9.1. Overview 19.1.9.2. Product Portfolio 19.1.9.3. Profitability by Market Segments 19.1.9.4. Sales Footprint 19.1.9.5. Strategy Overview 19.1.9.5.1. Marketing Strategy 19.1.10. Novartis AG 19.1.10.1. Overview 19.1.10.2. Product Portfolio 19.1.10.3. Profitability by Market Segments 19.1.10.4. Sales Footprint 19.1.10.5. Strategy Overview 19.1.10.5.1. Marketing Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports